https://doi.org/10.4081/ejtm.2021.9518
Evaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19
Submitted: 19 November 2020
Accepted: 18 April 2021
Published: 18 June 2021
Accepted: 18 April 2021
Abstract Views: 2027
PDF: 757
HTML: 35
HTML: 35
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The antiviral effectiveness of allicin (L-cysteine) has been shown by numerous studies in both levels of clinical and animals. The aim of this study was to evaluate the therapeutic effect of allicin (L-cysteine) on clinical presentation and prognosis. In the current study, 66 patients with COVID-19 based on clinical, radiological presentations and RT-PCR results, were enrolled in two groups of placebo and allicin. In the both allicin (L-cysteine) and placebo groups (n=33 in each group), the capsules were prescribed two times a day for two weeks. Clinical signs and symptoms, blood parameters and chest CT scan were evaluated before and two weeks after treatment. The results showed that allicin (L-cysteine) could significantly impact on improvement of signs and symptoms of COVID-19 after two weeks of treatment in comparison to placebo. Allicin (L-cysteine) not only improve the clinical signs, but also ameliorate the lab and radiological data, which suggest a therapeutic effect for this agent in COVID-19. Our data suggest the therapeutic effect of allicin (L-cysteine) on COVID-19 through improvement of clinical symptoms and acceleration of the healing process.
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 29.
DOI: https://doi.org/10.1016/S0140-6736(20)30185-9
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020.
DOI: https://doi.org/10.1093/cid/ciaa478
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. Erratum in: JAMA. 2021 Mar 16;325(11):1113.
DOI: https://doi.org/10.1001/jama.2020.1585
Oso BJ, Adeoye AO, Olaoye IF. Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases. J Biomol Struct Dyn. 2020 Sep 2:1-12. doi: 10.1080/07391102.2020.1813630. Epub ahead of print.
DOI: https://doi.org/10.1080/07391102.2020.1813630
CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346.
DOI: https://doi.org/10.15585/mmwr.mm6912e2
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. Epub 2020 Mar 16.
DOI: https://doi.org/10.1016/S0140-6736(20)30628-0
Nishiura H, Oshitani H, Kobayashi T, Saito T, Sunagawa T, Matsui T, Wakita T, COVID M, Suzuki M. Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19). MedRxiv. 2020 Jan 1.
DOI: https://doi.org/10.1101/2020.02.28.20029272
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Apr 14;323(14):1406-1407.
DOI: https://doi.org/10.1001/jama.2020.2565
Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160.
Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020 Aug;10(4):313-319. Epub 2020 Mar 26.
DOI: https://doi.org/10.1016/j.jpha.2020.03.009
Middleton J, Reintjes R, Lopes H. Meat plants-a new front line in the covid-19 pandemic. BMJ. 2020 Jul 9;370:m2716.
DOI: https://doi.org/10.1136/bmj.m2716
Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, Tripathi YB. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study. J Biomol Struct Dyn. 2020 Aug 27:1-14. Epub ahead of print.
DOI: https://doi.org/10.1080/07391102.2020.1810778
Khanal P, Duyu T, Patil BM, Dey YN, Pasha I, Wanjari M, Gurav SS, Maity A. Network pharmacology of AYUSH recommended immune-boosting medicinal plants against COVID-19. J Ayurveda Integr Med. 2020 Nov 25. Epub ahead of print.
DOI: https://doi.org/10.1016/j.jaim.2020.11.004
D'Adamo I, Gastaldi M, Morone P. The post COVID-19 green recovery in practice: Assessing the profitability of a policy proposal on residential photovoltaic plants. Energy Policy. 2020 Dec;147:111910. Epub 2020 Sep 23.
DOI: https://doi.org/10.1016/j.enpol.2020.111910
Monajjemi M, Mollaamin F, Shojaei S. An overview on Coronaviruses family from past to Covid-19: Introduce some inhibitors as antiviruses from Gillan’s plants. Biointerface Research in Applied Chemistry. 2020 Jan 1;10(3).
DOI: https://doi.org/10.33263/BRIAC103.575585
Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Prepr. doi10. 2020 Mar 13;20944:1-4.
Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Prepr. doi10. 2020 Mar 13;20944:1-4.
DOI: https://doi.org/10.20944/preprints202003.0226.v1
Shekh S, Reddy KK, Gowd KH. In silico allicin (L-cysteine) induced S-thioallylation of SARS-CoV-2 main protease. Journal of Sulfur Chemistry. 2020 Sep 16:1-2.
DOI: https://doi.org/10.1080/17415993.2020.1817457
Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Prepr. doi10. 2020 Mar 13;20944:1-4.
DOI: https://doi.org/10.20944/preprints202003.0226.v1
Boone HA, Medunjanin D, Sijerčić A. Review on Potential of Phytotherapeutics in Fight against COVID-19. Int J Innov Sci Res Technol. 2020;5:481-91.
Fasogbon BM, Ademuyiwa OH, Bamidele OP, Wahab IE, Ola-Adedoyin AT, Alakija O. Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review. Prev Nutr Food Sci. 2021 Mar 31;26(1):1-11.
DOI: https://doi.org/10.3746/pnf.2021.26.1.1
How to Cite
Yaghoubian, H., Niktale, H., Yazdi, A. P., Ghorani, V., Rashed, M. M., & Hashemian, A. M. (2021). Evaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19. European Journal of Translational Myology, 31(2). https://doi.org/10.4081/ejtm.2021.9518
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.